The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …

COVID-19 is currently considered the ninth-deadliest pandemic, spreading through direct or
indirect contact with infected individuals. It has imposed a consistent strain on both the …

In response to the COVID-19 pandemic, Merck Sharp & Dohme (MSD) acquired the global
licensing rights for the antiviral molnupiravir, promising affordable access via licensing …

Concerns have been raised about the actual benefit and safety of molnupiravir, a new
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …

Mutagenic antiviral drugs have shown promise against multiple viruses, but concerns have
been raised about whether their use might promote the emergence of new and harmful viral …

The long view on living with COVID-19 as an endemic disease calls for expanding the
planetary health intervention toolbox. We will need a battery of vaccines, small molecule oral …